Ricolinostat
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ricolinostat
- Accession Number
- DB12376
- Description
Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 433.512
Monoisotopic: 433.211389749 - Chemical Formula
- C24H27N5O3
- Synonyms
- Ricolinostat
- External IDs
- ACY-1215
- ACY-63
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Ricolinostat. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ricolinostat. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ricolinostat. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ricolinostat. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ricolinostat. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ricolinostat. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ricolinostat. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Ricolinostat. Amiodarone The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Ricolinostat. Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrimidinecarboxylic acids and derivatives. These are compounds containing a pyrimidine ring which bears a carboxylic acid group (or a derivative thereof).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyrimidinecarboxylic acids and derivatives
- Alternative Parents
- Aniline and substituted anilines / Aminopyrimidines and derivatives / Heteroaromatic compounds / Secondary carboxylic acid amides / Hydroxamic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Aminopyrimidine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative show 10 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- WKT909C62B
- CAS number
- 1316214-52-4
- InChI Key
- QGZYDVAGYRLSKP-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
- IUPAC Name
- 7-{[2-(diphenylamino)pyrimidin-5-yl]formamido}-N-hydroxyheptanamide
- SMILES
- ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 53340666
- PubChem Substance
- 347828624
- ChemSpider
- 28536129
- BindingDB
- 50439674
- ChEBI
- 95073
- ChEMBL
- CHEMBL2364628
- ZINC
- ZINC000089630354
- PDBe Ligand
- AH4
- PDB Entries
- 5wgl
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.014 mg/mL ALOGPS logP 3.04 ALOGPS logP 3.65 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 8.91 ChemAxon pKa (Strongest Basic) -1.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 107.45 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 122.73 m3·mol-1 ChemAxon Polarizability 48.16 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 22:08 / Updated on February 21, 2021 18:53